MGC Pharmaceuticals: Receives approvals for South Africa CimetrA trial

MGC Pharmaceuticals Receives approvals for South Africa CimetrA trial

• MGC Pharmaceuticals (MXC) receives study and import approvals from the South African Health Products Regulatory Authority for the Phase IIb CimetrA trial
• The trial will aim to target the effects of viral infections with inflammatory complications in patients with moderate COVID-19
• Once completed, the trial will provide the data needed to plan future regulatory pathways to register CimetrA as a drug
• CimetrA is MGC’s natural, immune-modulation formula that is made up of vitamin C and herbal extracts used to treat anti-inflammatory illnesses
• MGC Pharma is trading 11.1 per cent higher on the market at 2 cents at 2:52 pm AEST